Related Experiment Videos
Atracurium--a post-marketing surveillance study: methods and U.S. experience
H Jick1, E B Andrews, H H Tilson
1Boston Collaborative Drug Surveillance Program, Boston University Medical Center, Waltham, Ma.
British Journal of Anaesthesia
|June 1, 1989
Summary
Atracurium safety was evaluated in a post-marketing study. Adverse event rates were similar to other neuromuscular blocking agents, indicating comparable safety profiles for anesthesia drugs.
Area of Science:
- Anesthesiology
- Pharmacovigilance
- Clinical Pharmacology
Background:
- Post-marketing surveillance is crucial for evaluating drug safety in real-world clinical settings.
- Atracurium is a widely used neuromuscular blocking agent in anesthesia.
- Understanding the safety profile of atracurium compared to other agents is important for clinical decision-making.
Purpose of the Study:
- To evaluate the frequency of adverse events associated with atracurium use.
- To compare the safety profile of atracurium with other neuromuscular blocking agents.
- To assess the utility of observational studies for monitoring new anesthetic drugs.
Main Methods:
- Conducted a post-marketing observational study at Group Health Co-operative of Puget Sound.
- Monitored adverse events in 1013 patients receiving atracurium.
- Compared adverse event rates with 851 patients receiving alternative neuromuscular blocking agents.
Main Results:
- The frequency of adverse events for atracurium was similar to other neuromuscular blocking agents.
- No cardiac arrest, anaphylaxis, death, or block reversal failures were reported in either group.
- No previously unreported adverse effects were identified for atracurium.
Conclusions:
- Atracurium demonstrates a safety profile comparable to other neuromuscular blocking agents.
- Observational studies are valuable tools for the surveillance of new hospital-administered drugs.
- The findings support the continued safe use of atracurium in clinical practice.